Roche has agreed to acquire Telavant Holdings, a bio/pharmaceutical company owned by Roivant Sciences and Pfizer, for $7.1 billion.  

The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. 

Under the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. Upon closing of the transaction, Roche will have full rights to further develop and manufacture RVT-3101 and commercialize it in the US and in Japan pending clinical and regulatory success. Outside of the US and Japan, Pfizer holds commercialization rights. 

Source: Roivant Sciences